Discover your next big idea at PACK EXPO Las Vegas this September
Experience a breakthrough in packaging & processing and transform your business with solutions from 2,300 suppliers spanning all industries.
REGISTER NOW & SAVE

FDA Extends Enhanced Drug Distribution Security Requirements Deadline

The agency has announced a one-year delay in the DSCSA requirements for system-wide electronic interoperable systems to be put in place and how to request a waiver, exception, or exemption.

Fda Building

In a recently released FDA final guidance, entitled “Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act—Compliance Policies,” the FDA announced a one-year delay on the deadline for manufacturers and their trading partners to comply with the Drug Supply Chain Security Act’s final enhanced drug distribution security requirements, as described in the same document. Previously, the deadline was November 27 of this year.

The delay specifically addresses the requirements for system-wide electronic interoperable systems to be put in place to track products throughout the supply chain. It also applies to the processing of saleable returns. The same FDA guidance describes the compliance policies the FDA will employ regarding the enforcement of requirements for interoperable, electronic, package-level product tracing and provides information to help supply chain partners in their efforts to comply with the requirements for tracing at the package level.

The FDA also recently issued a guidance called “Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act,” which describes the process a trading partner or other stakeholder should use to request a waiver, exception, or exemption from the requirements of the Federal Food, Drug, and Cosmetic Act, as well as the factors the FDA will consider when it evaluates one of these requests from an authorized trading partner or other stakeholder. Additionally, this guidance describes the process the FDA intends to follow once every two years to review and make determinations on renewing a previously approved waiver, exception, or exemption, where applicable.

Requests for waivers, exceptions, and exemptions should be submitted through the FDA’s CDER NextGen Portal page.    

2024 PACK EXPO Innovations Reports
Exclusive access: Packaging World editor-curated reports revealing PACK EXPO's most groundbreaking technologies across food, healthcare, and machinery sectors. Each report features truly innovative solutions selected from hundreds of exhibitors by our expert team. Transform your operations with just one click.
Access Now
2024 PACK EXPO Innovations Reports
Annual Outlook Report: Automation & Robotics
What's in store for CPGs in 2025 and beyond? <i>Packaging World</i> editors explore the survey responses from 118 brand owners, CPG, and FMCG <i>Packaging World</i> readers for its new Annual Outlook Report.
Download
Annual Outlook Report: Automation & Robotics